Depression treatment for Wellington — measurement-based, 38 minutes away.

RECO Health is 28 miles east of Wellington — 38 minutes from Olympia or Palm Beach Polo — with a full continuum from PHP through IOP and in-house access to psychiatry, rTMS, and IV ketamine under one roof. For most Wellington PHP clients, the drive is far enough that pairing treatment with a stay in RECO's sober-living network makes more sense than commuting daily. Depression treatment is measurement-based: PHQ-9 at intake and weekly, C-SSRS at every clinical touchpoint, and escalation to interventional options on a defined schedule rather than after months of clinical drift.

Wellington sits 28 miles inland from RECO Health’s Delray Beach campus — a 38-minute drive that puts it far enough from the coast that daily commuting for intensive treatment is rarely the right structure for a client with severe depression. Depression treatment for Wellington residents typically pairs RECO’s PHP or IOP with a stay in the on-campus sober-living network, giving clients the clinical depth of a full continuum without a daily 76-mile round trip from Olympia, Versailles, or Palm Beach Polo.

Diagnostic formulation and severity staging

The initial psychiatric evaluation is designed to distinguish major depressive disorder from the conditions that mimic it — persistent depressive disorder, bipolar II depression, adjustment disorder with depressed mood, and depression secondary to hypothyroidism, B12 deficiency, alcohol use disorder, or benzodiazepine withdrawal. A missed bipolar diagnosis is the single most common reason antidepressants “stop working” after months of dose escalation, so a Mood Disorder Questionnaire and a structured history of hypomanic episodes are part of intake, not a later consideration.

Severity is anchored to the PHQ-9 rather than clinical impression. A PHQ-9 of 20 or higher, active suicidal ideation on the C-SSRS, or functional collapse routes clients to partial hospitalization at 30 hours per week. Moderate presentations — PHQ-9 in the 10 to 19 range with preserved functioning — are matched to intensive outpatient at 9 to 15 hours per week. Every intake includes a baseline TSH, B12, folate, vitamin D, and CBC; iron studies are added when fatigue is a primary complaint.

Suicide risk is not screened once and filed away. C-SSRS is repeated at every clinical touchpoint, and any endorsement of intent, plan, or means triggers same-day psychiatric review rather than a next-appointment follow-up. Firearms and medication access are addressed in the written safety plan the same session they are identified.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy is an SSRI — sertraline or escitalopram — or an SNRI — venlafaxine XR or duloxetine — titrated to a therapeutic dose within two weeks and held for a four-to-six-week response window. Sub-therapeutic dosing is the second most common reason antidepressants “fail”; a client on 50 mg of sertraline for eight weeks has had no adequate trial at all. Response is measured by PHQ-9 change, not global impression: a 50% reduction is response, a PHQ-9 under 5 is remission.

Partial response at an adequate dose is augmented rather than switched. Aripiprazole 2 to 5 mg has the strongest evidence for adjunctive use in MDD; lithium at levels of 0.6 to 0.8 mEq/L remains one of the best-supported augmentation strategies despite being under-used; bupropion is added for anhedonia, fatigue, or sexual side effects from the initial SSRI. Quetiapine XR is used for depression with prominent insomnia or anxiety when metabolic risk is acceptable, and buspirone is layered in for residual generalized anxiety captured on a rising GAD-7.

Two failed adequate trials — correct dose, correct duration, documented PHQ-9 non-response — define treatment-resistant depression. At that point, the next decision is not a fifth antidepressant. It is a staged move to the interventional pathway.

Behavioral therapy modalities with evidence for depression

Psychotherapy for depression at RECO Health is protocol-driven, not eclectic. Cognitive Behavioral Therapy targets cognitive distortions — all-or-nothing thinking, catastrophizing, mind-reading — and behavioral withdrawal, using thought records, activity monitoring, and behavioral experiments as structured homework between sessions. Behavioral Activation is delivered as a standalone protocol when a client is too depressed to engage cognitively; activity scheduling and rewarding-mastery hierarchies restore reinforcement contingencies before cognitive work becomes possible.

Interpersonal Therapy is used when depression is anchored to a recent life event: grief, role transition, or interpersonal dispute. Sixteen-session IPT has outcome data comparable to CBT for major depression and is often the better fit for older adults or clients whose depression followed a discrete loss. Acceptance and Commitment Therapy adds a values-based framework for clients whose depression is intertwined with chronic pain, illness, or existential concerns; Motivational Interviewing is used when ambivalence about treatment itself is a barrier.

For clients whose depression is downstream of trauma — a common presentation in this practice — Cognitive Processing Therapy or EMDR is layered in once safety and stability are established. Treating the trauma without addressing the depression, or vice versa, produces partial gains that don’t hold.

Escalation pathway when medication and therapy aren’t enough

Roughly one-third of clients with major depression will not achieve remission after two adequate antidepressant trials. RECO’s escalation pathway for this group is defined in advance rather than negotiated in the moment. Repetitive transcranial magnetic stimulation is the first-line interventional option: a standard protocol delivers 10 Hz stimulation over the left dorsolateral prefrontal cortex at 120% of resting motor threshold, 3,000 pulses per session, five sessions per week for six weeks (30 sessions) with a six-session taper. Most major insurers cover rTMS for TRD after two failed antidepressant trials.

IV ketamine (0.5 mg/kg over 40 minutes, a six-infusion induction over two to three weeks) is used when the clinical picture will not tolerate a six-week rTMS course — active suicidality, catatonic features, or functional collapse. Response, when it occurs, is typically evident within the first two infusions; maintenance is dosed to PHQ-9 trajectory rather than a fixed calendar. Intranasal esketamine (Spravato) is the preferred route when a REMS-monitored, insurance-covered protocol fits logistics better than a compounded IV.

Escalation happens on a schedule. Sitting on a partial response for six months is not a treatment plan.

What to expect on your first visit from Wellington

The first day is a full clinical intake, not a facility tour. A master’s-level clinician gathers psychiatric, substance use (AUDIT and DAST), and medical histories; a board-certified psychiatrist or PMHNP completes the diagnostic formulation and initial medication decisions. PHQ-9, GAD-7, and C-SSRS are administered at intake and repeated weekly; where an ADHD or bipolar comorbidity is suspected, ASRS and MDQ are added to the panel. Utilization review contacts insurance for authorization before the client leaves the building.

Wellington clients arriving for a PHP admission are typically settled into RECO’s sober-living network the same day. IOP clients living at home coordinate transportation for the 38-minute drive from Aero Club, Versailles, or Wellington View; those who prefer to stay closer during the first two to four weeks of stabilization can request a short-term residential option in Delray.

Insurance and admissions from Wellington

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS for mental health and substance use benefits. Verification is completed within a few hours of the initial call, and clients are quoted out-of-pocket exposure — deductible, co-insurance, and any per-diem limits — before admission rather than after billing. For clients whose plan requires prior authorization for rTMS or esketamine, that documentation is prepared during the initial trial of oral pharmacotherapy so the interventional pathway isn’t delayed by paperwork when the clinical case is ready.

Admissions runs seven days a week. A Wellington family calling on a Friday afternoon can typically be verified, financially briefed, and scheduled for a Monday morning intake with a same-day psychiatric evaluation on arrival.

Serving residents of: Olympia, Versailles, Aero Club, Palm Beach Polo, Wellington View.